MA28493B1 - Sulfonamides destinés au traitement de troubles neurodégénératifs - Google Patents

Sulfonamides destinés au traitement de troubles neurodégénératifs

Info

Publication number
MA28493B1
MA28493B1 MA29352A MA29352A MA28493B1 MA 28493 B1 MA28493 B1 MA 28493B1 MA 29352 A MA29352 A MA 29352A MA 29352 A MA29352 A MA 29352A MA 28493 B1 MA28493 B1 MA 28493B1
Authority
MA
Morocco
Prior art keywords
sulfonamides
treatment
neurodegenerative disorders
neurodegenerative
disorders
Prior art date
Application number
MA29352A
Other languages
English (en)
Inventor
Michael A Brodney
Karen J Coffman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA28493B1 publication Critical patent/MA28493B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/49—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA29352A 2004-04-01 2006-09-29 Sulfonamides destinés au traitement de troubles neurodégénératifs MA28493B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55866004P 2004-04-01 2004-04-01

Publications (1)

Publication Number Publication Date
MA28493B1 true MA28493B1 (fr) 2007-03-01

Family

ID=34962303

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29352A MA28493B1 (fr) 2004-04-01 2006-09-29 Sulfonamides destinés au traitement de troubles neurodégénératifs

Country Status (28)

Country Link
US (2) US7163942B2 (fr)
EP (1) EP1747195A1 (fr)
JP (2) JP2007530660A (fr)
KR (1) KR20060130705A (fr)
CN (1) CN1938266A (fr)
AP (1) AP2006003729A0 (fr)
AR (1) AR048348A1 (fr)
AU (1) AU2005227749A1 (fr)
BR (1) BRPI0509477A (fr)
CA (1) CA2562114A1 (fr)
CR (1) CR8669A (fr)
DO (1) DOP2005000049A (fr)
EA (1) EA200601607A1 (fr)
EC (1) ECSP066888A (fr)
GT (1) GT200500070A (fr)
IL (1) IL177955A0 (fr)
MA (1) MA28493B1 (fr)
MX (1) MXPA06011348A (fr)
MY (1) MY136718A (fr)
NL (1) NL1028664C2 (fr)
NO (1) NO20064989L (fr)
PE (1) PE20060147A1 (fr)
SV (1) SV2006002073A (fr)
TN (1) TNSN06314A1 (fr)
TW (1) TW200602297A (fr)
UY (1) UY28825A1 (fr)
WO (1) WO2005095334A1 (fr)
ZA (1) ZA200607213B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1289469C (zh) 2001-12-20 2006-12-13 布里斯托尔-迈尔斯斯奎布公司 α－(N－磺酰氨基)乙酰胺衍生物作为β－淀粉样蛋白抑制剂
CN1934091B (zh) * 2004-03-23 2012-02-08 辉瑞产品公司 治疗神经变性障碍的咪唑化合物
WO2007034326A2 (fr) * 2005-09-22 2007-03-29 Pfizer Products Inc. Composes imidazoles pour le traitement de troubles neurologiques
CN101627007A (zh) * 2007-03-05 2010-01-13 弗·哈夫曼-拉罗切有限公司 用作食欲肽拮抗剂的氨基酰胺
CN102088855A (zh) * 2008-05-08 2011-06-08 百时美施贵宝公司 2-芳基甘氨酰胺衍生物
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) * 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
WO2012162249A1 (fr) * 2011-05-20 2012-11-29 Benjamin Wolozin Identification de composés qui dispersent des inclusions de tdp-43
WO2013026021A2 (fr) * 2011-08-18 2013-02-21 Buck Institute For Research On Aging Trka comme cible pour l'inhibition du clivage d'app et/ou la progression de la maladie d'alzheimer
CN107722012B (zh) 2016-08-11 2020-05-29 斯福瑞（南通）制药有限公司 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS484784U (fr) * 1971-06-16 1973-01-19
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5491170A (en) * 1994-12-19 1996-02-13 Warner-Lambert Company β-carboxy sulfonamide ACAT inhibitors
EP0967201A1 (fr) 1998-05-20 1999-12-29 Roche Diagnostics GmbH Compositions pharmaceutiques contenant des sulphonamides comme inhibiteurs des métalloprotéinases matricielles
US7498358B2 (en) 2001-12-14 2009-03-03 Exelixis, Inc. Human ADAM-10 inhibitors
CN1289469C (zh) 2001-12-20 2006-12-13 布里斯托尔-迈尔斯斯奎布公司 α－(N－磺酰氨基)乙酰胺衍生物作为β－淀粉样蛋白抑制剂

Also Published As

Publication number Publication date
AR048348A1 (es) 2006-04-19
BRPI0509477A (pt) 2007-09-11
DOP2005000049A (es) 2005-12-15
CA2562114A1 (fr) 2005-10-13
US7345095B2 (en) 2008-03-18
MY136718A (en) 2008-11-28
US7163942B2 (en) 2007-01-16
US20050222254A1 (en) 2005-10-06
SV2006002073A (es) 2006-05-09
MXPA06011348A (es) 2006-12-15
NL1028664A1 (nl) 2005-10-05
TNSN06314A1 (fr) 2007-12-03
AP2006003729A0 (en) 2006-10-31
PE20060147A1 (es) 2006-03-08
ZA200607213B (en) 2008-04-30
NO20064989L (no) 2007-01-02
EA200601607A1 (ru) 2007-02-27
AU2005227749A1 (en) 2005-10-13
TW200602297A (en) 2006-01-16
ECSP066888A (es) 2006-11-24
CR8669A (es) 2006-11-01
CN1938266A (zh) 2007-03-28
IL177955A0 (en) 2006-12-31
JP2008189673A (ja) 2008-08-21
WO2005095334A1 (fr) 2005-10-13
NL1028664C2 (nl) 2006-03-22
JP2007530660A (ja) 2007-11-01
EP1747195A1 (fr) 2007-01-31
UY28825A1 (es) 2005-10-31
US20070129349A1 (en) 2007-06-07
GT200500070A (es) 2005-10-31
KR20060130705A (ko) 2006-12-19

Similar Documents

Publication Publication Date Title
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
EP1838320A4 (fr) Antagonistes de cxcr4 pour le traitement de troubles medicaux
MA28791B1 (fr) Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
HUS1800041I1 (hu) Piperazinnal helyettesített benzotiofének mentális rendellenességek kezelésére
DK1730119T3 (da) Imidazolforbindelser til behandling af neurodegenerative forstyrrelser
EP1601251A4 (fr) Compos s pour le traitement de troubles m taboliques
DE602005020209D1 (de) System zur Evaluierung von Herzstörungen
PT3415535T (pt) Nanocorpos tm aperfeiçoados para o tratamento de distúrbios mediados por agregação
EP2056848A4 (fr) Utilisation d'extraits pour le traitement de troubles viraux
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
EP2051967A4 (fr) Dérivés de benzimidazole utilisables pour le traitement des troubles liés au récepteur des vallinoïdes trpv1
PL1708991T3 (pl) Pochodne sulfonoamidu do leczenia chorób
IL190652A0 (en) Novel pharmaceutical combinations for the treatment of respiratory disorders
EP1951261A4 (fr) Préparations et méthodes pour le traitement de troubles inflammatoires
MA28493B1 (fr) Sulfonamides destinés au traitement de troubles neurodégénératifs
EP1991246A4 (fr) Traitement de troubles liés au développement
EP1940428A4 (fr) Préparations biliaires pour troubles gastro-intestinaux
NL1030418A1 (nl) Azabenzoxazolen voor de behandeling van CZS-stoornissen.
EP1933813A4 (fr) Liposomes de sphingomyeline pour le traitement de troubles de vessie hyperactive
EP1832861A4 (fr) Composant de traitement preanalytique
EP2026659A4 (fr) Composés destinés au traitement de troubles métaboliques
EP1889618A4 (fr) Médicament combiné pour le traitement du diabète
ZA200805108B (en) Treatment of neurodegenerative disorders
ZA200802270B (en) Treatment of neurodegenerative disorders
EP1734957A4 (fr) Composes de thiazole sulfamide utiles pour le traitement des maladies neurodegeneratives